Bone Marrow Transplant News and Research

RSS

SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

The Fred Hutchinson Cancer Research Center Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recently recognized for outperforming its anticipated one-year survival rate for allogeneic transplant patients.

28 Jan 2015

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Scientists seek to improve stem cell transplant outcomes using DNA sequencing, mathematical modeling

Is the human immune system similar to the weather, a seemingly random yet dynamical system that can be modeled based on past conditions to predict future states? Scientists at VCU Massey Cancer Center's award-winning Bone Marrow Transplant (BMT) Program believe it is, and they recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor.

5 Dec 2014

Researchers develop standardized, team-based approach to reduce alarm fatigue in hospitals

The sound of monitor alarms in hospitals can save patients' lives, but the frequency with which the monitors go off can also lead to "alarm fatigue," in which caregivers become desensitized to the ubiquitous beeping.

10 Nov 2014

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML).

7 Nov 2014

VCU Massey Cancer Center researchers develop tool for measuring cancer health literacy

Virginia Commonwealth University (VCU) Massey Cancer Center researchers have developed the first and only tool that can accurately measure cancer health literacy (CHL) and quickly identify patients with limited CHL. This tool has the potential to improve communication and understanding between physicians and patients, which, in turn, could lead to better clinical outcomes.

4 Nov 2014

Reduced chemotherapy exposure after surgery could decrease overall complications

A study of pediatric patients with hepatoblastoma led by researchers at Children's Hospital Los Angeles (CHLA) suggests an opportunity to reduce chemotherapy in up to 65 percent of patients, which could lead to a decrease in the incidence of adverse effects.

31 Oct 2014

Bortezomib drug effective against chronic GVHD

Researchers at UC Davis have found that the drug bortezomib effectively treats chronic graft-versus-host disease (GVHD), a common and debilitating side effect from allogeneic hematopoietic stem cell transplants.

27 Oct 2014

Novel approach may help detect invasive aspergillosis

Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach—analyzing a patient's breath for key chemical compounds made by the infecting microbe—may help detect invasive aspergillosis, a fungal infection that is a leading cause of mortality in patients with compromised immune systems, according to a proof-of-concept study now online in Clinical Infectious Diseases.

23 Oct 2014

Couple renews multi-million dollar commitment to screen newborn babies for SCID disorders

Frustrated with the slow pace of implementation of Newborn Screening for Severe Combined Immune Deficiency (SCID), Vicki and Fred Modell renewed a multi-million dollar commitment to screen every baby born in every state for this life threatening condition, often referred to as "Bubble Boy" disease.

21 Oct 2014

Scientists say fundamental theory about how thymus educates immune police appears to be wrong

A fundamental theory about how our thymus educates our immune police appears to be wrong, scientists say.

9 Oct 2014

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response.

8 Oct 2014

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

29 Sep 2014

Researchers discover new molecule that allows for multiplication of stem cells in cord blood

Investigators from the Institute for Research in Immunology and Cancer at the Université de Montréal have just published, in the prestigious magazine Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood.

22 Sep 2014

Human stem cells can be reset to their native undifferentiated state

Scientists at the Babraham Institute, in collaboration with colleagues at the Cambridge Stem Cell Institute and the European Bioinformatics Institute, have made a breakthrough in stem cell research. Their paper, published today in Cell, describes how human stem cells can be reverted back to non-specialised cells.

11 Sep 2014

HICCC receives $18 million grant from the National Cancer Institute

Outstanding basic research, a growing focus on translating discoveries into treatments, and a dedication to patient care have earned the Herbert Irving Comprehensive Cancer Center (HICCC) of Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center Support Grant from the National Cancer Institute (NCI).

28 Aug 2014

Scientists grow fully functional organ in animal from transplanted laboratory-created cells

Laboratory-grown replacement organs have moved a step closer with the completion of a new study. Scientists have grown a fully functional organ from transplanted laboratory-created cells in a living animal for the first time.

26 Aug 2014

UChicago Medicine and Advocate Health Care wins NIH grant to find new ways to prevent type 1 diabetes

The University of Chicago Medicine and Advocate Children's Hospital / Advocate Health Care have received a five-year, $1.8-million grant from the National Institutes of Health to find new ways to delay and prevent type 1 diabetes. The grant will establish the first Type 1 Diabetes TrialNet Clinical Center in Chicago.

12 Aug 2014

University of Chicago adds six new members to governing Board of Trustees

The University of Chicago Medical Center added six new members to its governing Board of Trustees, and named a new president of the medical staff.

8 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).